<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
APRIL 4, 2000
ALBANY MOLECULAR RESEARCH, INC.
(Exact Name of Registrant as Specified in Its Charter)
<TABLE>
<CAPTION>
DELAWARE 000-25323 14-1742717
<S> <C> <C>
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
</TABLE>
21 CORPORATE CIRCLE, ALBANY, NEW YORK 12203
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code: (518) 464-0279
N/A
- -------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
On April 4, 2000, Albany Molecular Research, Inc. (the "Company") dismissed
KPMG LLP ("KPMG") and engaged PricewaterhouseCoopers LLP as the Company's
independent accountants for the fiscal year ending December 31, 2000. In each
case, the decision was approved by the Board of Directors of the Company, upon
the recommendation of the Audit Committee.
KPMG's reports on the consolidated financial statements of the Company for
the past two years did not contain an adverse opinion or a disclaimer of
opinion, and were not qualified or modified as to uncertainty, audit scope or
accounting principles.
During the Company's two most recent fiscal years and the subsequent
interim period preceding the dismissal of KPMG, there were no disagreements
with KPMG regarding any matters of accounting principles or practices,
financial statement disclosure or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of KPMG, would have caused
KPMG to make reference to the subject matter of the disagreements in
connection with its report.
The Company delivered a copy of this current report on Form 8-K to KPMG on
April 7, 2000. The Company requested that KPMG furnish it with a letter
addressed to the Securities and Exchange Commission stating whether it agrees
with the above statements. The letter, dated April 10, 2000, has been filed as
an exhibit to this current report on Form 8-K.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
<S> <C>
16.1 Letter dated April 10, 2000 from KPMG LLP
to the Securities and Exchange Commission
</TABLE>
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ALBANY MOLECULAR RESEARCH, INC.
Date: April 10, 2000 By: /s/ David P. Waldek
--------------------------
David P. Waldek
Chief Financial Officer
<PAGE>
Exhibit 16.1
Securities and Exchange Commission
Washington, D.C. 20549
April 10, 2000
Ladies and Gentlemen:
We were previously principal accountants for Albany Molecular Research, Inc.
and, under the date of February 4, 2000, we reported on the consolidated balance
sheets of Albany Molecular Research, Inc. and subsidiaries as of December 31,
1999 and 1998, and the related consolidated statements of operations,
shareholders' equity and comprehensive income, and cash flows for each of the
years in the three-year period ended December 31, 1999. On April 4, 2000, our
appointment as principal accountants was terminated. We have read Albany
Molecular Research, Inc.'s statements included under Item 4 of its Form 8-K
dated April 4, 2000, and we agree with such statements, except that we are not
in a position to agree or disagree with Albany Molecular Research, Inc.'s
statements that the change was approved by the board of directors, upon the
recommendation of the audit committee.
Very truly yours,
/s/ KPMG LLP
